ArticleBMJ case reports2018
New onset diabetes after nivolumab treatment.
Article in BMJ case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review.Frontiers in public health · 2023Pooled it
- Combined diabetic ketoacidosis and hyperosmolar hyperglycemic state in type 1 diabetes mellitus induced by immune checkpoint inhibitors: Underrecognized and underreported emergency in ICIs-DM.Frontiers in endocrinology · 2022Pooled it
- PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review.Frontiers in public health · 2022Pooled it
- Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.European journal of endocrinology · 2019Pooled it
- Durvalumab‑induced type 1 diabetes mellitus in lung adenocarcinoma: A case report and literature review.Oncology letters · 2025Article
- Tislelizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer: a case report.Frontiers in oncology · 2025Article
- Immune checkpoint inhibitor-associated diabetic ketoacidosis and insulin-dependent diabetes: a case report.Journal of medical case reports · 2024Article
- Presentation of new onset type 1 diabetes with diabetic ketoacidosis and hyperosmolar hyperglycaemia after a single dose of nivolumab and ipilimumab.Endocrinology, diabetes & metabolism case reports · 2023Article
- Diabetic ketoacidosis induced by nivolumab in invasive mucinous adenocarcinoma of the lung: a case report and review of the literature.Annals of translational medicine · 2022Article
- New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer.Endocrinology, diabetes & metabolism case reports · 2022Article
- Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases.Clinical case reports · 2021Article
- Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.Medicine · 2021Review
- Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management.Frontiers in oncology · 2021Article
- Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?Clinical medicine (London, England) · 2020Review
- Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.Endocrinology, diabetes & metabolism case reports · 2020Article
- A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.Internal medicine (Tokyo, Japan) · 2019Article
- Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature.BMJ case reports · 2019Review
- Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.International journal of molecular sciences · 2019Review
- Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study.Journal of clinical medicine research · 2019Review
- Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.Clinical diabetes and endocrinology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The authors describe a case of a life-threatening diabetic emergency 25 days after initiation of nivolumab (3 mg/kg) for stage 4 lung adenocarcinoma. She was admitted to the emergency department, with hyperglycaemia-related signs and symptoms, such as polyuria, polydipsia, weight loss, confusion, asthenia, dehydration, hypotension and Kussmaul respiratory pattern. Her body mass index was 21.9 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.